https://www.selleckchem.com/products/AG-490.html
DLT was reached at DL2 (G4 thrombocytopenia and G3 diarrhea, 1 each). There were no G5 toxicities. Median overall survival was 2.2months. During the study period, changing practice patterns favored utilization of stereotactic radiosurgery (SRS). Thus, the trial closed early prior to completion. In a patient population representative of modern candidates for WBRT, trametinib plus WBRT is highly toxic with a MTD 1.5mg. The safety of trametinib with SRS remains an important question for future study. In a patient population representati
Like
Comment
Share
